[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Aurinia Pharm Ord (AUPH)

Aurinia Pharm Ord (AUPH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Aurinia Pharm Ord 14315 - 118 AVENUE SUITE 140 EDMONTON A0 T5L 4S6 CAN

www.auriniapharma.com Employees: 128 P: 250-744-2487 F: 604-369-4115

Sector:

Medical

Description:

Aurinia Pharmaceuticals Inc. is a late stage biopharmaceutical company. It focuses on the development of therapeutic immunomodulating drug candidate. The company's lead drug includes Voclosporin for the treatment of lupus nephritis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.

Key Statistics

Overview:

Market Capitalization, $K 1,978,956
Enterprise Value, $K 1,898,746
Shares Outstanding, K 129,938
Float, K 114,086
% Float 87.80%
Short Interest, K 9,112
Short Float 7.01%
Days to Cover 8.44
Short Volume Ratio 0.29
% of Insider Shareholders 12.20%
% of Institutional Shareholders 36.83%

Financials:

Annual Sales, $ 283,060 K
Annual Net Income, $ 287,200 K
Last Quarter Sales, $ 77,110 K
Last Quarter Net Income, $ 210,790 K
EBIT, $ 114,440 K
EBITDA, $ 133,890 K

Growth:

1-Year Return 87.79%
3-Year Return 41.81%
5-Year Return 27.77%
5-Year Revenue Growth 464.76%
5-Year Earnings Growth 194.25%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.26 on 02/26/26
Next Earnings Date 07/30/26
Earnings Per Share ttm 0.81
EPS Growth vs. Prev Qtr -3.85%
EPS Growth vs. Prev Year 56.25%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%
Most Recent Split 1-50 on 11/08/13

AUPH Ratios

Ratio
Price/Earnings ttm 16.82
Price/Earnings forward 18.63
Price/Earnings to Growth N/A
Return-on-Equity % 28.80%
Return-on-Assets % 20.73%
Profit Margin % 101.46%
Debt/Equity 0.00
Price/Sales 6.95
Price/Cash Flow 14.94
Price/Book 3.43
Book Value/Share 4.41
Interest Coverage 27.36
60-Month Beta 1.44
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.